NDRG1 and neuropathy: Our findings suggest NDRG1 may be a potential novel biomarker for CIPN, with low NDRG1 expression in nerve tissue identifying patients at greater risk for paclitaxel-induced neuropathy for whom an alternative drug/regimen may be considered.